Amphastar Reports Q3 2026 Revenue Growth Driven by BAQSIMI and Primatene MIST Sales
Amphastar (AMPH) reported third-quarter 2026 net revenues of $207.6 million, an 8% increase year-over-year. The growth was primarily fueled by record sales of BAQSIMI ($58.8 million) and Primatene MIST ($31.5 million), alongside a significant 29% surge in Lidocaine revenue due to competitor shortages. Despite top-line growth, gross margins compressed to 48.0% from 51.4% last year, impacted by pricing pressures and increased manufacturing expenses related to remediation efforts at the IMS facility. The company also faced declines in Epinephrine and Glucagon revenues. Management expects higher remediation costs over the next few quarters but issued Q4 revenue guidance projecting high single-digit growth.
Tickers: $AMPH
Topics: earnings report pharmaceutical sales product performance revenue growth